Clinical Trial

What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer?

Study acronym: MISS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 9, 2024 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
Italian, multicenter, study aimed at defining the best interval for screening women 45-49 and 70-74 years for Breast Cancer (BC). This research project includes (1) a controlled, prospective randomized non-inferiority trial to determine the optimal screening interval for women aged 45-49, with and without high mammographic density, (2) a retrospective data collection, with the same purpose, on screening performed by women aged 70-74, and (3) a qualitative research to define the best communication strategy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-10-12.
Trial Details
NCT Number NCT04590560
Lead Sponsor Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Conditions Breast Cancer
Enrollment 60,000 participants
Start Date 2020-02-06
Primary Completion 2026-02 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2024-12-09